{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GIVE&page=6",
    "query": {
      "intervention": "GIVE",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 20584,
    "total_pages": 2059,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GIVE&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GIVE&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T08:06:04.272Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00134706",
      "title": "A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2004-01",
      "completion_date": "2009-09",
      "has_results": false,
      "last_update_posted_date": "2009-12-09",
      "last_synced_at": "2026-10-22T08:06:04.272Z",
      "location_count": 6,
      "location_summary": "Boston, Massachusetts • Lowell, Massachusetts • Dover, New Hampshire + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Lowell",
          "state": "Massachusetts"
        },
        {
          "city": "Dover",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00134706"
    },
    {
      "nct_id": "NCT02598895",
      "title": "Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Castration Levels of Testosterone",
        "Castration-Resistant Prostate Carcinoma",
        "Metastatic Prostate Carcinoma",
        "Prostate Carcinoma Metastatic in the Bone",
        "PSA Progression",
        "Stage IV Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 14,
      "start_date": "2016-01-26",
      "completion_date": "2021-09-14",
      "has_results": true,
      "last_update_posted_date": "2022-11-17",
      "last_synced_at": "2026-10-22T08:06:04.272Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02598895"
    },
    {
      "nct_id": "NCT03363945",
      "title": "Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Kidney Transplant Rejection"
      ],
      "interventions": [
        {
          "name": "MDR-101",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Medeor Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 30,
      "start_date": "2018-03-15",
      "completion_date": "2024-04-11",
      "has_results": false,
      "last_update_posted_date": "2024-06-07",
      "last_synced_at": "2026-10-22T08:06:04.272Z",
      "location_count": 18,
      "location_summary": "Loma Linda, California • Los Angeles, California • Stanford, California + 15 more",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03363945"
    },
    {
      "nct_id": "NCT02833701",
      "title": "Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma",
        "Glioma"
      ],
      "interventions": [
        {
          "name": "Ascorbic Acid",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2016-03",
      "completion_date": "2019-03",
      "has_results": false,
      "last_update_posted_date": "2023-10-24",
      "last_synced_at": "2026-10-22T08:06:04.272Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02833701"
    },
    {
      "nct_id": "NCT04981912",
      "title": "Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "HDMP + rituximab as a means of debulking prior to initiating venetoclax.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 4,
      "start_date": "2021-09-02",
      "completion_date": "2025-07-31",
      "has_results": true,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-10-22T08:06:04.272Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04981912"
    },
    {
      "nct_id": "NCT06792500",
      "title": "A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "MELAS Syndrome",
        "Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)"
      ],
      "interventions": [
        {
          "name": "Glycerol Tributyrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "George Washington University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2027-03",
      "completion_date": "2028-11",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-22T08:06:04.272Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06792500"
    },
    {
      "nct_id": "NCT04003207",
      "title": "Growth Hormone Treatment in Children With Phelan McDermid Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Phelan McDermid Syndrome"
      ],
      "interventions": [
        {
          "name": "Recombinant human Growth hormone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Swathi Sethuram",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "2 Years to 12 Years"
      },
      "enrollment_count": 6,
      "start_date": "2019-09-13",
      "completion_date": "2020-06-05",
      "has_results": true,
      "last_update_posted_date": "2024-05-02",
      "last_synced_at": "2026-10-22T08:06:04.272Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04003207"
    },
    {
      "nct_id": "NCT04288271",
      "title": "Teen Adherence in KidnEy Transplant Improving Tracking To Optimize Outcomes - Stage 3",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Medication Adherence",
        "Kidney Transplantation"
      ],
      "interventions": [
        {
          "name": "Adherence Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Healthy living education intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "McGill University Health Centre/Research Institute of the McGill University Health Centre",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "24 Years",
        "sex": "ALL",
        "summary": "12 Years to 24 Years"
      },
      "enrollment_count": 96,
      "start_date": "2022-02-04",
      "completion_date": "2023-06-30",
      "has_results": false,
      "last_update_posted_date": "2024-03-15",
      "last_synced_at": "2026-10-22T08:06:04.272Z",
      "location_count": 4,
      "location_summary": "St Louis, Missouri • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04288271"
    },
    {
      "nct_id": "NCT00309244",
      "title": "Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Type 2"
      ],
      "interventions": [
        {
          "name": "Technosphere® Insulin Inhalation Powder",
          "type": "DRUG"
        },
        {
          "name": "70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mannkind Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 677,
      "start_date": "2006-02",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2014-10-16",
      "last_synced_at": "2026-10-22T08:06:04.272Z",
      "location_count": 80,
      "location_summary": "Mobile, Alabama • Tucson, Arizona • Chula Vista, California + 54 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00309244"
    },
    {
      "nct_id": "NCT01808534",
      "title": "Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Central Nervous System Germ Cell Tumor",
        "Adult Teratoma",
        "Malignant Extragonadal Germ Cell Tumor",
        "Malignant Extragonadal Non-Seminomatous Germ Cell Tumor",
        "Extragonadal Seminoma",
        "Recurrent Malignant Testicular Germ Cell Tumor",
        "Recurrent Ovarian Germ Cell Tumor",
        "Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor",
        "Stage IV Extragonadal Seminoma",
        "Stage IV Ovarian Germ Cell Tumor"
      ],
      "interventions": [
        {
          "name": "palifosfamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2013-02",
      "completion_date": "2014-11",
      "has_results": true,
      "last_update_posted_date": "2015-07-02",
      "last_synced_at": "2026-10-22T08:06:04.272Z",
      "location_count": 3,
      "location_summary": "Indianapolis, Indiana • Philadelphia, Pennsylvania • Seattle, Washington",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01808534"
    }
  ]
}